Q-omics provides the consensus-scored RPL19P21 profile across patient tissues and cancer cell-line models. RPL19P21 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL19P21 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, RPL19P21 RNA expression shows 8,805 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where RPL19P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL19P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL19P21 survival associations across molecular data types. RPL19P21 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL19P21 RNA expression–survival associations across cancer types. High RPL19P21 expression shows unfavorable associations in OV, ACC and LIHC, but favorable associations in KIRC, BLCA and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL19P21 RNA expression.
This table summarizes RPL19P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL19P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL19P21 shows higher tumor expression in LIHC, KIRC, KIRP, COAD, CHOL and THCA. The LIHC box plot shows higher RPL19P21 RNA expression in tumor versus normal tissue (log2 FC = +0.325, t-test p < 0.001).
This table shows molecular features associated with RPL19P21 in patient tissues and cancer cell lines. In patient samples, RPL19P21 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
